
CTXR
Citius Pharmaceuticals Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.490
Open
1.430
VWAP
1.45
Vol
390.82K
Mkt Cap
16.31M
Low
1.4009
Amount
568.46K
EV/EBITDA(TTM)
--
Total Shares
180.67M
EV
19.99M
EV/OCF(TTM)
--
P/S(TTM)
--
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
--
--
4.500
-446.15%
--
--
0.330
-105.69%
--
--
-0.210
-86%
Estimates Revision
The market is revising No Change the revenue expectations for Citius Pharmaceuticals, Inc. (CTXR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 73.40%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-6.47%
In Past 3 Month
Stock Price
Go Up

+73.40%
In Past 3 Month
3 Analyst Rating

242.47% Upside
Wall Street analysts forecast CTXR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTXR is 5.00 USD with a low forecast of 4.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy

242.47% Upside
Current: 1.460

Low
4.00
Averages
5.00
High
6.00

242.47% Upside
Current: 1.460

Low
4.00
Averages
5.00
High
6.00
D. Boral Capital
D. Boral Capital
Buy
downgrade
$9 -> $6
2025-06-10
Reason
D. Boral Capital
D. Boral Capital
Price Target
$9 -> $6
2025-06-10
downgrade
Buy
Reason
D. Boral Capital lowered the firm's price target on Citius Pharmaceuticals to $6 from $9 and keeps a Buy rating on the shares. The firm cites dilution for the target cut after the company announced a registered direct offering totaling up to $15.8M in gross proceeds.
Maxim
Buy
to
Hold
downgrade
2025-05-23
Reason
Maxim
Price Target
2025-05-23
downgrade
Buy
to
Hold
Reason
Maxim downgraded Citius Pharmaceuticals to Hold from Buy.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-02-18
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-02-18
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-01-07
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-01-07
Maintains
Strong Buy
Reason
D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm believes that as Lymphir launches, it will become a value driver for its parent, Citius. Oncology drug Lymphir has achieved significant milestones in its development and approval process, contends D. Boral.
D. Boral Capital
Jason Kolbert
Hold
to
Strong Buy
Upgrades
$9
2024-12-30
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2024-12-30
Upgrades
Hold
to
Strong Buy
Reason
D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm believes that as Lymphir launches, it will become a value driver for its parent, Citius. Oncology drug Lymphir has achieved significant milestones in its development and approval process, contends D. Boral.
D. Boral Capital
Jason Kolbert
Strong Buy
to
Hold
Downgrades
n/a
2024-11-22
Reason
D. Boral Capital
Jason Kolbert
Price Target
n/a
2024-11-22
Downgrades
Strong Buy
to
Hold
Reason
D. Boral Capital downgraded Citius Pharmaceuticals to Hold from Buy without a price target following the company's announcement of a 1-for-25 reverse stock split. The reverse is partly a result of the failure of the spinoff of Citius Oncology to unlock shareholder value, the analyst tells investors in a research note. The firm says the downgrade is more technical than fundamental.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Citius Pharmaceuticals Inc (CTXR.O) is 0.89, compared to its 5-year average forward P/E of -5.68. For a more detailed relative valuation and DCF analysis to assess Citius Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-5.68
Current PE
0.89
Overvalued PE
11.78
Undervalued PE
-23.14
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
4.46
Current PS
0.43
Overvalued PS
10.28
Undervalued PS
-1.37
Financials
Annual
Quarterly
FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY :
+2.65%
-11.26M
Operating Profit
FY2025Q2
YoY :
+34.73%
-11.51M
Net Income after Tax
FY2025Q2
YoY :
-5.22%
-1.27
EPS - Diluted
FY2025Q2
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CTXR News & Events
Events Timeline
2025-07-15 (ET)
2025-07-15
08:36:27
Citius Oncology signs distribution agreement for Lymphir with Cencora

2025-06-17 (ET)
2025-06-17
08:10:20
Citius Oncology expects commercial launch of Lymphir in second half of 2025

2025-06-10 (ET)
2025-06-10
07:05:25
Citius Pharmaceuticals announces $15.8M registered direct offering

Sign Up For More Events
Sign Up For More Events
News
8.5
07-17PRnewswireCitius Oncology Announces Closing of $9.0 Million Public Offering
8.5
07-16NewsfilterCitius Oncology Announces Pricing of $9.0 Million Public Offering
7.5
07-15NewsfilterCitius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Sign Up For More News
People Also Watch

HOVR
New Horizon Aircraft Ltd
1.700
USD
-3.95%

BGI
Birks Group Inc
0.875
USD
+0.81%

HUBC
Hub Cyber Security Ltd
4.290
USD
+3.87%

CRIS
Curis Inc
1.820
USD
+4.60%

AXIL
AXIL Brands Inc
7.300
USD
+5.04%

AQU
Aquaron Acquisition Corp
0
USD
-0.60%

ANY
Sphere 3D Corp
0.690
USD
+2.68%

TURB
Turbo Energy SA
2.274
USD
+0.62%

PMEC
Primech Holdings Ltd
1.520
USD
-3.18%

CGTX
Cognition Therapeutics Inc
0.775
USD
+10.71%
FAQ

What is Citius Pharmaceuticals Inc (CTXR) stock price today?
The current price of CTXR is 1.46 USD — it has increased 1.39 % in the last trading day.

What is Citius Pharmaceuticals Inc (CTXR)'s business?

What is the price predicton of CTXR Stock?

What is Citius Pharmaceuticals Inc (CTXR)'s revenue for the last quarter?

What is Citius Pharmaceuticals Inc (CTXR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Citius Pharmaceuticals Inc (CTXR)'s fundamentals?

How many employees does Citius Pharmaceuticals Inc (CTXR). have?
